CB2 Insights (CSE: CBII), a data firm with a focus on medical cannabis just announced it has reached an agreement to acquire the medical cannabis and education center group, MedEval Clinic LLC. The deal which cost about US$ 375,000 in stock and cash will see CB2 take ownership of MedEval Clinic LLC’s Arizona and Colorado locations.
The deal marks the second largest acquisition by the Toronto-based company after 2017 procurement of Massachusetts-based Canna Care Docs. MedEval has one clinic in Phoenix, Arizona and two in Colorado.
The terms of the deal will see CB2 Insights pay US$ 150,000 in cash in addition to 450,000 of its shares valued at US$ 225,000. There are additional perks valued at US$ 300,000. About the acquisition, the CEO of CB2 Insights, Prad Sekar stated, “This acquisition not only increases our data pool but has an accretive lift to our financial performance. Colorado plays a vital role in medical cannabis data, representing a very mature recreational market which also sees medical cannabis patient counts continue to grow.”
CB2 has its focus on the provision of Real-World Evidence (RWE) and clinical data analysis on the effectiveness of cannabinoid therapy. Prior to this acquisition, CB2 Insights provides about 65,000 patients with medical evaluations each year.
Curious about how you can make money investing in cannabis? Sign up for Cannin Free Access and subscribe to the Cannin Chronicle. We'll keep you informed on all things cannabis and even help you determine which cannabis companies have the highest growth potential.